- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer1 new
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
INCY Market Currents
more »
-
Wednesday 1:51 PM Incyte (INCY -2.7%) slips after Morgan Stanley says current consensus estimates don't reflect myelofibrosis competition, which could impact Incyte's Jakafi sales.
Comment![Healthcare, On the Move]
INCY in Focus
more »
INCY Related Articles
more »
INCY News
more »
-
at CNBC.com (Wed, 6:44PM)
-
at MarketWatch.com (Tue, 12:10PM)
-
at CNBC.com (May 16, 2011)
-
at MarketWatch.com (May 3, 2011)
-
at MarketWatch.com (May 3, 2011)
INCY Press Releases and Filings
more »
-
Business Wire (Wed, 8:00AM)
-
Business Wire (May 1, 2012)
-
Business Wire (Apr 26, 2012)
-
Business Wire (Apr 20, 2012)
-
Business Wire (Apr 10, 2012)
INCY Latest Transcript
more »
INCY Cramer
more »
-
Thu, May 24
-
Thu, Mar 11, 2010
-
Tue, May 8, 2007
INCY Instablog posts
more »
INCY vs. ETF Alternatives
Company Description
Incyte is a drug discovery and development company focused on developing proprietary small molecule drugs to treat serious unmet medical needs. We have a broad pipeline with programs focused primarily in the areas of oncology and inflammation. We focus our efforts on clinical programs that we... More
